Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting. Data was announced by both Bristol Myers Squibb (BMS) ...
J&J presented the new CEPHEUS data at the 2024 annual meeting of the International Myeloma Society this week. (Johnson & Johnson) Following the FDA's green light for a combo regimen of Sanofi’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results